Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Assessment of CYP450 genetic variability effect on methadone dose and tolerance.

Tsai HJ, Wang SC, Liu SW, Ho IK, Chang YS, Tsai YT, Lin KM, Liu YL.

Pharmacogenomics. 2014 May;15(7):977-86. doi: 10.2217/pgs.14.19.

PMID:
24956251
2.

Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.

Mouly S, Bloch V, Peoc'h K, Houze P, Labat L, Ksouda K, Simoneau G, Declèves X, Bergmann JF, Scherrmann JM, Laplanche JL, Lepine JP, Vorspan F.

Br J Clin Pharmacol. 2015 Jun;79(6):967-77. doi: 10.1111/bcp.12576.

3.

Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.

Wang SC, Ho IK, Tsou HH, Liu SW, Hsiao CF, Chen CH, Tan HK, Lin L, Wu CS, Su LW, Huang CL, Yang YH, Liu ML, Lin KM, Liu SC, Wu HY, Kuo HW, Chen AC, Chang YS, Liu YL.

OMICS. 2013 Oct;17(10):519-26. doi: 10.1089/omi.2012.0068. Epub 2013 Sep 9.

4.
5.

Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients.

Chen CH, Wang SC, Tsou HH, Ho IK, Tian JN, Yu CJ, Hsiao CF, Chou SY, Lin YF, Fang KC, Huang CL, Su LW, Fang YC, Liu ML, Lin KM, Hsu YT, Liu SC, Chen ACh, Liu YL.

Pharmacogenomics. 2011 Oct;12(10):1397-406. doi: 10.2217/pgs.11.103. Epub 2011 Sep 8.

PMID:
21902501
6.

CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.

Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ.

Addict Biol. 2013 Jul;18(4):709-16. doi: 10.1111/j.1369-1600.2011.00349.x. Epub 2011 Jul 25.

7.

Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients.

Wang SC, Tsou HH, Chen CH, Chen YT, Ho IK, Hsiao CF, Chou SY, Lin YF, Fang KC, Huang CL, Su LW, Fang YC, Liu ML, Wu HY, Lin KM, Liu SC, Kuo HW, Chiang IC, Chen AC, Tian JN, Liu YL.

Eur Neuropsychopharmacol. 2012 Oct;22(10):695-703. doi: 10.1016/j.euroneuro.2012.02.002. Epub 2012 Mar 9.

PMID:
22406240
8.

Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT).

Zahari Z, Lee CS, Ibrahim MA, Musa N, Mohd Yasin MA, Lee YY, Tan SC, Mohamad N, Ismail R.

Drug Alcohol Depend. 2016 Aug 1;165:143-50. doi: 10.1016/j.drugalcdep.2016.05.028. Epub 2016 Jun 6.

PMID:
27289271
9.

Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.

Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, Eap CB.

Clin Pharmacol Ther. 2005 Dec;78(6):593-604.

PMID:
16338275
10.

Illicit Heroin and Methamphetamine Use among Methadone Maintenance Treatment Patients in Dehong Prefecture of Yunnan Province, China.

Wang R, Ding Y, Bai H, Duan S, Ye R, Yang Y, Wang J, Tang R, Gao M, He N.

PLoS One. 2015 Jul 21;10(7):e0133431. doi: 10.1371/journal.pone.0133431. eCollection 2015.

11.

The differential effect of methadone dose and of chronic pain on pain perception of former heroin addicts receiving methadone maintenance treatment.

Peles E, Schreiber S, Hetzroni T, Adelson M, Defrin R.

J Pain. 2011 Jan;12(1):41-50. doi: 10.1016/j.jpain.2010.04.009. Epub 2010 Jun 19.

PMID:
20561825
12.

Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele.

Hwang IC, Park JY, Ahn HY, Kim KK, Suh HS, Ko KD, Kim KA.

Clin Chim Acta. 2014 Jan 20;428:77-81. doi: 10.1016/j.cca.2013.11.007. Epub 2013 Nov 19.

PMID:
24262967
13.

Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients.

Yuce-Artun N, Baskak B, Ozel-Kizil ET, Ozdemir H, Uckun Z, Devrimci-Ozguven H, Suzen HS.

Int J Clin Pharm. 2016 Apr;38(2):388-94. doi: 10.1007/s11096-016-0259-8. Epub 2016 Jan 30.

PMID:
26830411
14.

Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan.

Lee HY, Li JH, Sheu YL, Tang HP, Chang WC, Tang TC, Yeh YC, Wang SY, Liu RH.

Biomed Res Int. 2013;2013:741403. doi: 10.1155/2013/741403. Epub 2013 Dec 16.

15.

Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.

Bogen DL, Perel JM, Helsel JC, Hanusa BH, Romkes M, Nukui T, Friedman CR, Wisner KL.

Psychopharmacology (Berl). 2013 Jan;225(2):441-51. doi: 10.1007/s00213-012-2833-7. Epub 2012 Aug 25.

16.

Effects of CYP2C19 variants on methadone metabolism in vitro.

Lan T, Yuan LJ, Hu XX, Zhou Q, Wang J, Huang XX, Dai DP, Cai JP, Hu GX.

Drug Test Anal. 2017 Apr;9(4):634-639. doi: 10.1002/dta.1997. Epub 2016 May 19.

PMID:
27199033
17.

Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.

Crettol S, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Déglon JJ, Preisig M, Eap CB.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1722-7. doi: 10.1016/j.pnpbp.2008.07.009. Epub 2008 Jul 17.

PMID:
18687376
18.

Meaning and methadone: patient perceptions of methadone dose and a model to promote adherence to maintenance treatment.

Sanders JJ, Roose RJ, Lubrano MC, Lucan SC.

J Addict Med. 2013 Sep-Oct;7(5):307-13. doi: 10.1097/ADM.0b013e318297021e.

PMID:
23803718
19.

Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.

Shu W, Guan S, Yang X, Liang L, Li J, Chen Z, Zhang Y, Chen L, Wang X, Huang M.

Br J Clin Pharmacol. 2016 Feb;81(2):327-40. doi: 10.1111/bcp.12800. Epub 2015 Dec 25.

20.

Enantiomeric metabolic interactions and stereoselective human methadone metabolism.

Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED.

J Pharmacol Exp Ther. 2007 Apr;321(1):389-99. Epub 2007 Jan 26.

Supplemental Content

Support Center